A protein involved in cellular adhesion that is normally produced only before birth but is often abnormally expressed in cancer and may contribute to metastasis.
Small cell prostate cancer clinical trials.
Progression during or following completion of at least 1 prior line of systemic therapy for locally advanced or metastatic prostate cancer.
Although all clinical trials have criteria for the participants clinical trials are available to patients at all stages of cancer.
Patients with de novo small cell prostate cancer are not required to have received androgen deprivation therapy adt.
All trials on the list are supported by nci.
Clinical trials look at new ways to prevent detect or treat disease.
Cancer vaccine targets under evaluation in prostate cancer clinical trials include.
Clinical trials also known as clinical studies or research protocols are conducted to test whether a new drug new prevention strategy or new screening test is safe and effective in people.
But small cell prostate cancer is very rare so it is harder to research than other more common types of prostate cancer.
The purpose of this research study is to assess the impact of 68ga psma 11 pet ct an experimental imaging scan for prostate cancer on the success of.
The proposed clinical trial will study the effects of 12 months of therapy with arn 509 alone or in combination with an lhrh agonist lhrha each compared to lhrha alone in men with a rapidly rising serum psa after prior definitive local therapy for prostate cancer.
Clinical trials are research studies that involve people.
For cohort a scnc.
An antigen often expressed by several different types of cancers cea.
A clinical research study is now enrolling men with recurrent prostate cancer after radical prostatectomy who have a psa of at least 0 1 ng ml and are planned to undergo salvage radiotherapy.
This is a multi institutional single arm open label phase 2 trial evaluating mln8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer.
Doctors are always trying to improve the diagnosis and treatment of cancer.
Not all neuroendocrine prostate cancers carry the same prognosis.
Aggarwal identified a sub type that became prevalent in 17 of patients who were heavily pretreated with enzalutamide xtandi and abiraterone zytiga he calls this treatment emergent small cell neuroendocrine prostate cancer t scnc the pre treatment probably selected for this subtype that may be partially responsive to.
The clinical trials on this list are for prostate cancer treatment.
Participation is always voluntary.
The eligibility criteria which is meant to ensure patients safety may include the patient s age gender cancer type and stage previous treatments and overall health.
Subjects will be treated with mln8237 at 50 mg twice daily for 7 days repeated every 21 days.
